Pharmacoeconomic review report Risankizumab (Skyrizi) (AbbVie)
Risankizumab is a humanized immunoglobulin G1 monoclonal antibody1 with an indication for the treatment of adult patients with moderate to severe plaque psoriasis who are candidates for systemic therapy or phototherapy. Risankizumab is available as a solution for injection in a single-use, pre-fille...
| Autor principal: | |
|---|---|
| Autor Corporativo: | |
| Formato: | Libro electrónico |
| Idioma: | Inglés |
| Publicado: |
Ottawa (ON) :
Canadian Agency for Drugs and Technologies in Health
2019.
|
| Materias: | |
| Ver en Biblioteca Universitat Ramon Llull: | https://discovery.url.edu/permalink/34CSUC_URL/1im36ta/alma991009820268206719 |
